抑制IGFBP7可通过调节ERK1/2通路来缓解LPS诱导的核脉细胞损伤
Jun Gao1, Chunsheng Gao1, Xiaowei Wang1
1Department of Orthopaedics, The Third People's Hospital of Hubei Province, Wuhan, 430033 China.
Cytotechnology
|June 9, 2025
概括
椎间盘退化 (IDD) 涉及细胞核脉 (NP) 细胞. 这项研究发现,抑制胰岛素样生长因子结合蛋白7 (IGFBP7) 通过ERK1/2通路减少NP细胞亡和炎症,这表明IGFBP7是IDD的治疗标.
科学领域:
- 整形外科和再生医学
- 细胞生物学和分子机制
背景情况:
- 椎间盘退化 (IDD) 显著损害生活质量,其中核脉 (NP) 细胞起着至关重要的作用.
- 胰岛素样生长因子结合蛋白7 (IGFBP7) 在IDD病原体中的特定作用和机制仍然不清楚,尽管它与其他骨科疾病有关.
研究的目的:
- 为了研究IGFBP7的作用和潜在机制,在一个细胞模型的脂多糖 (LPS) 诱导的IDD.
- 确定IGFBP7是否作为缓解IDD进展的潜在治疗标.
主要方法:
- 建立了一个体外IDD模型,使用用LPS刺激的人类初级NP细胞.
- 通过RT-qPCR和Western blot来评估IGFBP7表达.
- 利用IGFBP7-siRNA使IGFBP7沉默,并评估细胞活力 (MTT试验),细胞亡 (流细胞计),炎症性细胞因子分泌 (ELISA),以及与细胞亡相关的蛋白质 (Bax,Bcl-2) 和细胞外矩阵组件 (aggrecan, II型原蛋白) 的表达.
- 通过测量酸化水平和使用ERK激活剂 (LM22B-10) 调查了ERK1/2通路的参与.
主要成果:
- 经过LPS刺激,IGFBP7的表达显著增加 (大约1. 3倍),并激活了NP细胞中的ERK1/2通路.
- LPS治疗降低了NP细胞活力,增加了细胞亡,增加了炎症因子 (TNF-α,IL-6,IL-1β),降低了ECM成分 (aggrecan,II型原) 和Bcl-2,同时增加了Bax.
- 用siRNA抑制IGFBP7可以逆转这些有害影响,通过抑制ERK1/2通路来减轻亡和炎症. 相反,ERK激活抵消了IGFBP7沉默的保护作用.
结论:
- 在LPS诱导的IDD中,IGFBP7通过促进亡和炎症,部分通过激活ERK1/2通路来发挥有害作用.
- 沉默IGFBP7在这种细胞模型中显示出对IDD的保护作用.
- IGFBP7已成为治疗椎间盘退行症的有前途的治疗点.
相关概念视频
NF-κB-dependent Signaling Pathway
7.3K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.3K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
IP3/DAG Signaling Pathway
11.9K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
11.9K
Phosphoinositides and PIPs
8.5K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.5K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K


